Gupta A, Shields KJ, Manzi S, et al. - Among patients suffering from systemic lupus erythematosus (SLE), the link between hydroxychloroquine (HCQ) use and new- onset atrial fibrillation was investigated. Researchers analyzed a retrospective cohort of adult patients with SLE. Patients were split as either HCQ users or nonusers. Incident atrial fibrillation was set as the primary outcome. Propensity score matching analysis was applied. Findings of this exploratory study revealed an 88% reduction in the risk of incident atrial fibrillation in relation to use of HCQ in SLE patients. Taking into account the elevated cardiovascular risk in SLE, inclusion of HCQ into the regimen may be useful for both disease manifestations as well as decreasing the risk of atrial fibrillation. There will be a requirement for further investigations to corroborate the antibrillatory advantage of this relatively safe and low- cost medication.